Catalent installing new tableting, encapsulation equipment as part of $40m investment

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags Catalent

Catalent is installing new equipment to increase its formulation capabilities and capacity to manufacture controlled-release tablets and capsules.

The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.

According to the company, it also will increase its roller compaction and fluid bed capacity – and an automated bottling line is currently being installed.

Additionally, a new spray dryer will provide commercial scale-up capacity for projects progressing from early-stage development. This will enable tech transfer of projects from Catalent’s development sites, including San Diego, CA and Nottingham, UK, according to the company.

Equipment validation is expected over the coming months.

Formulation and supply services

In related news, Catalent recently announced that it has successfully provided formulation and supply services for MGB Biopharma’s Phase II clinical trial materials.

Catalent and MGB Biopharma have been working together to formulate and manufacture MGB Biopharma’s leading candidate, MGB-BP-3, an orally-dosed drug for the treatment of Clostridium difficile-associated diarrhea (CDAD).

Also earlier this month, Catalent expanded its hot melt extrusion (HME) capabilities​ at its drug development center of excellence. Additionally, the company opened​ its 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars